Acura Pharmaceuticals Inc (PK:ACUR)
Business Focus: Bio Therapeutic Drugs
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 616 N North Ct Ste 120 PALATINE IL 60067-8121 |
| Tel: | 1-847-7057709 |
| Website: | acurapharm.com |
| IR: | See website |
| Key People | ||
| Robert B. Jones President, Chief Executive Officer, Director | Peter A. Clemens Chief Financial Officer, Senior Vice President, Secretary | Robert A. Seiser Vice President, Corporate Controller, Treasurer |
| Albert W. Brzeczko Vice President - Pharmaceutical Sciences | James F. Emigh Vice President - Corporate Development | |
| Business Overview |
| Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine. |
| Financial Overview |
| For the fiscal year ended 31 December 2021, Acura Pharmaceuticals Inc revenues decreased 56% to $1.6M. Net loss decreased 27% to $879K. Revenues reflect License fees from related party decrease of 53% to $1.4M, Product Sales decrease from $223K to $0K, Collaboration from related party decrease of 87% to $31K. Lower net loss reflects General and administrative decrease of 51% to $1.3M (expense), R&D decrease of 14% to $1.5M (expense). |
| Employees: | 14 as of Dec 31, 2017 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $0.80M as of Dec 31, 2021 |
| Annual revenue (TTM): | $1.56M as of Dec 31, 2021 |
| EBITDA (TTM): | -$1.09M as of Dec 31, 2021 |
| Net annual income (TTM): | -$0.88M as of Dec 31, 2021 |
| Free cash flow (TTM): | -$0.74M as of Dec 31, 2021 |
| Net Debt Last Fiscal Year: | $0.14M as of Dec 31, 2021 |
| Shares outstanding: | 66,001,783 as of Apr 30, 2023 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.